摘要
目的:探讨β受体阻滞剂治疗急性心肌梗死患者的危害和获益。方法:选取诊断为急性心肌梗死,没有行介入治疗的患者87例,经常规治疗后,给予酒石酸美托洛尔12.5~25mg,2次/d,观察2h^3d,及随访12个月。结果:有4例(4.6%)在治疗2h^3d内出现急性心力衰竭,有6(6.9%)例较原来的心力衰竭加重,有3例(3.4%)出现重度房室传到阻滞,6(6.9%)例出现头晕、乏力不适,其中有2(2.2%)例抢救无效死亡。其余69例(79.3%)无明显不适,病情稳定。结论:美托洛尔在治疗急性心肌梗死时,短期内有可能使心功能恶化,产生危害;但是远期对大部分患者可以使射血分数提高,改善心功能,使患者获益。
Objective： To investigate the β -blockers in treatment of patients with acute myocardial infarction harm and benefit. Method： A total of 87 patients with diagnosis of acute myocardial infarction without the intervention treatment, after the regular treatment, were given metoprolol 12.5-25 mg bid, observation of 2 hours to 3 days, and were followed up for 12 months. Result： There were 4 cases （ 4.6% ） in the treatment of 2 hours to 3 days of the onset of acute heart failure, 6 （ 6.9% ） patients with heart failure exacerbation of the original. There were 3 cases （ 3.4% ） presented with severe atrioventricular to block, 6 （ 6.9% ） cases of dizziness, weakness of discomfort. There were 2 （ 2.2% ） cases died. The remaining 69 patients （ 79.3% ） had no obvious discomfort, stable condition. Conclusion： Metoprolol in the treatment of acute myocardial infarction may cause deterioration of cardiac function in the short term, but for most patients, can make the ejection fraction increasing, and the heart function improved, in the long term, so the patients will benefit.
出处
《中国医学创新》
CAS
2013年第10期26-27,共2页
Medical Innovation of China
